What are the contraindications to topical testosterone replacement therapy?

Contraindications to Topical Testosterone Replacement Therapy

Topical testosterone replacement therapy is absolutely contraindicated in men with breast cancer, known or suspected prostate cancer, and in women who are pregnant, as testosterone can cause fetal harm. 1

Absolute Contraindications

Malignancy

• Breast carcinoma in men - Testosterone and its conversion to estradiol can stimulate breast cancer growth, making this an absolute contraindication with limited safety data available 2, 1
• Known or suspected prostate cancer - While historically considered absolute, this remains a formal contraindication in current FDA labeling and guidelines, though debate exists for men deemed cured 3, 1

Pregnancy

• Women who are pregnant or may become pregnant - Testosterone gel can cause virilization of the female fetus when administered to pregnant women 1
• Risk of secondary exposure - Pregnant women must avoid contact with unwashed or unclothed application sites on men using topical testosterone due to transfer risk 4, 1

Fertility Concerns

• Men actively trying to conceive - Exogenous testosterone therapy interrupts normal spermatogenesis and can cause severe oligospermia or azoospermia through down-regulation of gonadotropins 4, 3

Relative Contraindications and Situations Requiring Caution

Cardiovascular Disease

• Recent cardiovascular events - The AUA guideline recommends testosterone therapy should not be commenced for a period of 3-6 months in patients with a history of myocardial infarction or cerebrovascular accident 4
• Severe heart failure - Testosterone therapy should be used cautiously in men with congestive heart failure due to potential fluid retention 3

Hematologic Concerns

• Elevated hematocrit >48-50% - This represents a relative contraindication as testosterone increases red blood cell mass and may increase thromboembolic risk 2, 1
• History of venous thromboembolism - Postmarketing reports have documented DVT and PE in patients using testosterone products 1

Urologic Conditions

• Severe lower urinary tract symptoms - Men with International Prostate Symptom Score >19 should not start therapy without further evaluation 5
• Benign prostatic hyperplasia with severe symptoms - Patients with BPH are at increased risk for worsening signs and symptoms when treated with androgens 1
• Elevated PSA >4.0 ng/mL or abnormal digital rectal examination - Prostate biopsy should be performed before initiating therapy to exclude occult prostate cancer 3

Sleep Disorders

• Untreated severe obstructive sleep apnea - Testosterone has been associated with exacerbation or development of sleep apnea, particularly in men with other risk factors 3, 5

Renal Disease

• Renal insufficiency - Testosterone should be used cautiously due to potential fluid retention, though this is generally mild 3

Important Clinical Pitfalls

Secondary Exposure Risk

A critical safety concern specific to topical formulations is the risk of virilization in children and women through skin-to-skin contact. Cases have been reported with enlargement of genitalia, development of pubic hair, increased erections and libido, aggressive behavior, and advanced bone age in children 4, 1. The FDA includes medication guides with topical testosterone preparations specifically addressing this risk 4.

Pre-Treatment Screening Requirements

Before initiating topical testosterone therapy 3, 5:

• Baseline PSA and digital rectal examination in men >40 years
• Baseline hematocrit or hemoglobin
• Assessment for sleep apnea history
• Voiding symptom evaluation
• Prostate biopsy if PSA >4.0 ng/mL or abnormal digital rectal examination

Monitoring During Therapy

The New England Journal of Medicine recommends monitoring every 3-6 months for the first year, then annually, assessing for 3:

• PSA changes (biopsy if yearly increase ≥1.0 ng/mL)
• Hematocrit elevation
• Worsening urinary symptoms
• Development or exacerbation of sleep apnea